# A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

> **NCT05989828** · PHASE1 · SUSPENDED · sponsor: **University of Southern California** · enrollment: 20 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Aldesleukin
- **BIOLOGICAL:** Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Echocardiography
- **DRUG:** Fludarabine
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Mammogram
- **PROCEDURE:** Multigated Acquisition Scan
- **PROCEDURE:** Ultrasound Imaging

## Key facts

- **NCT ID:** NCT05989828
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2024-12-17
- **Primary completion:** 2026-12-17
- **Final completion:** 2027-12-17
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Pending Protocol Amendment Approval
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989828, "A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05989828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*